MONTREAL, April 23, 2019 — ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that the U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to its lead technology, ECT-001, in the treatment of hematologic malignancies. The RMAT designation is based on strong data from Phase I/II clinical trials using ECT-001 to expand stem and immune cells for the treatment of blood cancers. [Read more…]
Talaris Therapeutics Receives RMAT, Raises $100M, Announces Promising Phase II Data for Kidney Transplant
Talaris Therapeutics’ RMAT and Promising Phase 2 Data of Cell Therapy for Living Donor Kidney Transplant Recipients
BOSTON & LOUISVILLE, Ky.–Apr 18, 2019–Talaris Therapeutics, Inc., formerly Regenerex, a privately held biotechnology company developing transformative cell therapies that have the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients, today announced full results of its Phase 2 trial of FCR001 in living donor kidney transplant (LDKT) recipients. The therapy’s strong durability of benefit and safety profile support the initiation of a Phase 3 clinical trial in LDKT later this year.
L7 Informatics, Data Management and Process Automation Solutions for Cell and Gene Therapy Companies
Headquartered in Austin, Texas, L7 Informatics, provides software and services that enable synchronized solutions for cell and gene therapy companies. Specifically, L7’s novel Enterprise Science Platform (ESP) is a scientific process and data management (SPDM) solution that enables life science and healthcare companies to connect people, processes, and systems. The company’s mission is to use this technology to accelerate discoveries and drive precision healthcare.
In this interview, Vasu Rangadass – President and CEO of L7 Informatics – and I explore the company’s origins, its unique ESP technology, future directions, and more. Enjoy! [Read more…]
“Vision For The Future” Takes On New Meaning As Doug Oliver, Founder of The Regenerative Outcomes Foundation, Shares What Lies Ahead In His Journey
I am honored to release this interview with Doug Oliver, Founder of the Regenerative Outcomes Foundation. Doug has an incredible story of being a stem cell patient, turned renowned advocate and consultant within the field of regenerative medicine. In this interview, we explore what inspired him to establish the Regenerative Outcomes Foundation, his awards and accolades within the field, the critical importance of advocacy work, and so much more. Enjoy! [Read more…]
Pluristem Therapeutics, Interview with Yaky Yanay, President and Co-CEO
Pluristem Therapeutics (PSTI) is a clinical-stage company that is a proprietary 3D manufacturing technology to develop placental cell therapies for conditions that include ischemia, muscle injury, and exposure to radiation. I had the honor of interviewing Mr. Yaky Yanay, President and Co-CEO of Pluristem Therapeutics.
In this interview, we discuss the history of Pluristem Therapeutics, its clinical-stage products, intellectual property (IP) portfolio, marketing strategy and future directions.
Enjoy these insights into Pluristem Therapeutics, a world-class leader in cell therapy manufacturing and placental-derived products. [Read more…]
- « Previous Page
- 1
- …
- 212
- 213
- 214
- 215
- 216
- …
- 336
- Next Page »